Drugs Made In America Acquisition Corp. Units (NASDAQ:DMAAU) — Market Cap & Net Worth
Market Cap & Net Worth: Drugs Made In America Acquisition Corp. Units (DMAAU)
Drugs Made In America Acquisition Corp. Units (NASDAQ:DMAAU) has a market capitalization of $308.64 Million ($308.64 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14788 globally and #3497 in its home market, demonstrating a -1.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Drugs Made In America Acquisition Corp. Units's stock price $10.79 by its total outstanding shares 29171400 (29.17 Million). Also see DMAAU total asset value for a full breakdown of the balance sheet.
Drugs Made In America Acquisition Corp. Units Market Cap History: 2025 to 2026
Drugs Made In America Acquisition Corp. Units's market capitalization history from 2025 to 2026. Data shows growth from $306.01 Million to $314.76 Million (0.00% CAGR). Also see cash efficiency ratio of Drugs Made In America Acquisition Corp. for how efficiently the company converts equity into cash flow.
Drugs Made In America Acquisition Corp. Units Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Drugs Made In America Acquisition Corp. Units's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Drugs Made In America Acquisition Corp. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DMAAU by Market Capitalization
Companies near Drugs Made In America Acquisition Corp. Units in the global market cap rankings as of September 18, 2026. Review DMAAU goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Drugs Made In America Acquisition Corp. Units by market ranking:
- Twenty One Capital, Inc. (NYSE:XXI): Ranked #6332 globally with a market cap of $1.93 Billion USD.
- Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ:DMII): Ranked #11012 globally with a market cap of $647.19 Million USD.
- Ares Acquisition Corporation II (NYSE:AACT): Ranked #11487 globally with a market cap of $587.05 Million USD.
- Voyager Acquisition Corp (NASDAQ:VACH): Ranked #11916 globally with a market cap of $541.25 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6332 | Twenty One Capital, Inc. | NYSE:XXI | $1.93 Billion | $5.57 |
| #11012 | Drugs Made In America Acquisition II Corp. Ordinary Shares | NASDAQ:DMII | $647.19 Million | $10.18 |
| #11487 | Ares Acquisition Corporation II | NYSE:AACT | $587.05 Million | $9.49 |
| #11916 | Voyager Acquisition Corp | NASDAQ:VACH | $541.25 Million | $24.79 |
Drugs Made In America Acquisition Corp. Units Historical Marketcap From 2025 to 2026
Between 2025 and today, Drugs Made In America Acquisition Corp. Units's market cap moved from $306.01 Million to $ 314.76 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $314.76 Million | +2.86% |
| 2025 | $306.01 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Drugs Made In America Acquisition Corp. Units was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $308.64 Million USD |
| MoneyControl | $308.64 Million USD |
| MarketWatch | $308.64 Million USD |
| marketcap.company | $308.64 Million USD |
| Reuters | $308.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.